| NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity T Moriyama, R Nishii, V Perez-Andreu, W Yang, FA Klussmann, X Zhao, ... Nature genetics 48 (4), 367-373, 2016 | 478 | 2016 |
| Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study T Moriyama, ML Metzger, G Wu, R Nishii, M Qian, M Devidas, W Yang, ... The Lancet Oncology 16 (16), 1659-1666, 2015 | 205 | 2015 |
| Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity CC Suiter, T Moriyama, KA Matreyek, W Yang, ER Scaletti, R Nishii, ... Proceedings of the National Academy of Sciences 117 (10), 5394-5401, 2020 | 108 | 2020 |
| Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry T Moriyama, YL Yang, R Nishii, H Ariffin, C Liu, TN Lin, W Yang, DT Lin, ... Blood, The Journal of the American Society of Hematology 130 (10), 1209-1212, 2017 | 102 | 2017 |
| The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia T Moriyama, R Nishii, TN Lin, K Kihira, H Toyoda, N Jacob, M Kato, K Koh, ... Pharmacogenetics and genomics 27 (6), 236-239, 2017 | 82 | 2017 |
| Loss of DNA damage response in neuroblastoma and utility of a PARP inhibitor M Takagi, M Yoshida, Y Nemoto, H Tamaichi, R Tsuchida, M Seki, K Uryu, ... JNCI: Journal of the National Cancer Institute 109 (11), djx062, 2017 | 62 | 2017 |
| Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy R Nishii, T Moriyama, LJ Janke, W Yang, CC Suiter, TN Lin, L Li, K Kihira, ... Blood, The Journal of the American Society of Hematology 131 (22), 2466-2474, 2018 | 56 | 2018 |
| BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors R Tsuchida, T Osawa, F Wang, R Nishii, B Das, S Tsuchida, M Muramatsu, ... Oncogene 33 (29), 3803-3811, 2014 | 56 | 2014 |
| Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia R Nishii, R Baskin-Doerfler, W Yang, N Oak, X Zhao, W Yang, ... Blood, The Journal of the American Society of Hematology 137 (3), 364-373, 2021 | 55 | 2021 |
| ATM regulates adipocyte differentiation and contributes to glucose homeostasis M Takagi, H Uno, R Nishi, M Sugimoto, S Hasegawa, J Piao, N Ihara, ... Cell reports 10 (6), 957-967, 2015 | 40 | 2015 |
| Combination of common and novel rare NUDT15 variants improves predictive sensitivity of thiopurine-induced leukopenia in children with acute lymphoblastic leukemia Y Zhu, D Yin, Y Su, X Xia, T Moriyama, R Nishii, F Liao, S Zhang, X Guo, ... Haematologica 103 (7), e293, 2018 | 31 | 2018 |
| Diplotype analysis of NUDT15 variants and 6-mercaptopurine sensitivity in pediatric lymphoid neoplasms S Tsujimoto, T Osumi, M Uchiyama, R Shirai, T Moriyama, R Nishii, ... Leukemia 32 (12), 2710-2714, 2018 | 30 | 2018 |
| NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir R Nishii, T Mizuno, D Rehling, C Smith, BL Clark, X Zhao, SA Brown, ... Nature communications 12 (1), 4181, 2021 | 20 | 2021 |
| TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL). F Morschhauser, S Dahiya, ML Palomba, AM Garcia‐Sancho, JL Ortega, ... Hematological Oncology 41, 2023 | 18 | 2023 |
| An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia Y Tanaka, AEJ Yeoh, T Moriyama, CK Li, K Kudo, Y Arakawa, ... haematologica 106 (7), 2026, 2021 | 11 | 2021 |
| Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity D Rehling, SM Zhang, AS Jemth, T Koolmeister, A Throup, O Wallner, ... Journal of Biological Chemistry 296, 2021 | 10 | 2021 |
| TRANSCEND FL: phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma F Morschhauser, S Dahiya, ML Palomba, AM Garcia-Sancho, JL Reguera, ... Blood 142, 602, 2023 | 8 | 2023 |
| PharmGKB summary: acyclovir/ganciclovir pathway M Maillard, L Gong, R Nishii, JJ Yang, M Whirl-Carrillo, TE Klein Pharmacogenetics and genomics 32 (5), 201-208, 2022 | 6 | 2022 |
| Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study F Morschhauser, S Dahiya, ML Palomba, A Martin Garcia-Sancho, ... Nature Medicine, 1-9, 2024 | 5 | 2024 |
| NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia M Yoshida, K Nakabayashi, W Yang, A Sato-Otsubo, S Tsujimoto, ... Blood Advances 5 (23), 5420-5428, 2021 | 5 | 2021 |
